Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease
NCT ID: NCT01384721
Last Updated: 2021-01-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
1000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2010-09-30
Study Completion Date
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study aims at pooling a large population of patients with suspected coronary artery disease (CAD) who underwent Computed Tomography Coronary Angiography (CTCA) and who were adequately stratified in the first place. Then the investigators will be able to assess the incremental value of CTCA in the stratification of prevalence of disease (non obstructive/obstructive) and prognosis of patients with suspected CAD). The added information to current evidence is how reliable and to what extent CTCA can define the actual burden of disease and cardiovascular risk.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peri-luminal COROnary CTa AI-driven radiOMICS to Identify Vulnerable Patients (CORO-CTAIOMICS)
NCT06029777
Coronary Artery Disease
COMPLETED
Quantitative Analysis of Functional CT Imaging of Coronary Atherosclerosis
NCT04986410
Coronary Artery Disease
COMPLETED
CCTA-based Coronary Plaque Characterization and High-sensitive Troponin T for the Prediction of Cardiovascular Outcomes
NCT02030704
Coronary Artery Disease
Noninvasive Plaque Characterization
COMPLETED
PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques
NCT06794684
Coronary Arterial Disease (CAD)
Coronary Arteriosclerosis
RECRUITING
Machine leArning Based CT angiograpHy derIved FFR: a Multi-ceNtEr, Registry
NCT02805621
Coronary Heart Disease
Coronary Artery Disease
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Project aims at pooling (retrospectively) a large population of patients with suspected coronary artery disease (CAD) who underwent Computed Tomography Coronary Angiography (CTCA) and who were adequately stratified in the first place. Then the investigators will be able to assess the incremental value of CTCA in the stratification of prevalence of disease (non obstructive/obstructive) and prognosis of patients with suspected CAD. The added information to current evidence is how reliable and to what extent CTCA can define the actual burden of disease and cardiovascular risk.
Primary objectives
* MACE/Major Adverse Cardiovascular Events (i.e. Cardiac Death, Unstable Angina requiring Hospitalization, Acute Myocardial Infarction)
* Prevalence of cardiovascular risk category shifting based on coronary plaque burden
Secondary objectives
* Coronary Revascularizations occurred after CTCA (i.e. PCI/Percutaneous Coronary Revascularization and CABG/Coronary Artery Bypass Graft)
* Prevalence of outliers (i.e. patients lying completely outside the conventional risk stratification; pts with \>3 risk factors and no CAD at CTCA and pts with no risk factors and \>5 coronary segments with CAD)
Institutional Database will be used as data supply. Data will be anonimyzed and pooled (i twill not be possible to detect patients' identity). For this reason the investigators will no task for patients' Informed Consent.
DESIGN The investigators will retrospectively collect data from respective Institutional databases regarding patients who underwent CTCA for suspected CAD in the last 4 years.
General Inclusion criteria Only patients with also Calcium Score
≥64-slice CT technology (or 16-slice CT technology with \>4 year follow-up) Number of patients of at least 100 with complete clinical file and follow-up Minimum follow-up of 12 months Only patients with suspected Coronary Artery Disease
METHODS Study design and patient population This is an observational retrospective study (consecutive patients meeting the inclusion criteria) in patients with suspected coronary artery disease referred to our Institutions for evaluation by Computed Tomography Coronary Angiography (CTCA) starting in January 2003. Participating centers will provide data from 16-slice CTCA (minimum follow-up \>4 years) or superior (i.e. 64-slice CTCA; minimum follow-up 12 months). Each center will have to provide at least 200 patients (with complete file for evaluation).
Patients are usually referred because of symptoms (chest pain, dyspnoea on exertion) and/or abnormal or equivocal stress test and/or high cardiovascular risk profile. Exclusion criteria are renal failure (creatinine clearance \<60ml/min), known previous reaction to iodinated contrast medium and pregnancy, history of Myocardial Infarction, previous revascularization (PCI and/or CABG).
All the patients will be assessed by interview and by data collection from clinical database of the Institution for presence of cardiovascular risk factors and symptoms. The following risk factors will be considered: 1) Hypertension (defined as Arterial Pressure 140/80 mmHg or need for antihypertensive therapy); 2) Hypercholesterolemia (LDL Cholesterol \>130 mg/dl or current treatment with lipid-lowering therapy); 3) Diabetes Mellitus (current need for antidiabetic or insulin therapy); 4) Smoking habit; 5) Obesity (Body Mass Index/BMI\> 30); 6) Family history of cardiac disease. Symptoms will be classified as no symptoms, typical chest pain, atypical chest pain, dyspnoea on exertion. The pre-test cardiovascular risk of the patients will be determined by means of the Morise risk score.
Follow-up Follow-up data of all the patients were obtained by outpatient visit and/or phone contact and/or data collection from clinical database of the Institution. Minimum follow-up will be 6 months. Hospital/patients' records were screened for the occurrence of clinical events to confirm the obtained information. The clinical end-points are: 1) cardiac death, 2) non-fatal acute myocardial infarction, 3) unstable angina requiring hospitalization, 4) percutaneous or surgical revascularization. Cardiac death is defined as death caused by acute myocardial infarction or ventricular arrhythmias. Non-fatal myocardial infarction is defined based on criteria of typical chest pain, elevated cardiac enzyme levels, and typical changes on the electrocardiogram. Revascularization is defined as percutaneous coronary intervention (PCI) with stenting or coronary artery bypass surgery (CABG). The end point was the occurrence of one MACE at follow-up.
Multislice computed tomography data acquisition All examinations were performed with a 16-slice or higher CT system (Multi-vendor). First, a prospectively triggered coronary calcium CT data set was obtained using standardized CT parameters. Thereafter CTCA was performed after the administration of a bolus (60-100ml) non ionic contrast material (Multi-vendor) at flow rate of 4-6ml/s depending on patient status. All injections were performed by power injector via an antecubital vein and were followed by 50 ml of saline bolus chase at the same flow rate. A bolus tracking technique was used to determine the initiation of CT data acquisition. CTCA was performed with the best available parameters, depending on scanner type and generation. The reconstruction slice thickness and increment were 0.5-0.75mm and 0.3-0.5mm respectively. Intra-venous beta-blocker (e.g. atenolol 5-10mg) was administered to all patients with a heart rate \>65 beats/min and without contraindication (known asthma or bronchospasm, systolic blood pressure \<100mmHg). In addition, nitro-glycerine was administered sublingually to all patients, albeit contraindications (known significant aortic stenosis, systolic blood pressure \<100mmHg). Patients with atrial fibrillation or frequent premature beats were included in the study. To obtain optimal image quality, datasets were reconstructed at least at two points of the cardiac cycle using a retrospective ECG gating algorithm (one diastolic cardiac phase usually at -350msec from the R waves and one end-systolic phase at +275msec). In the presence of motion artefacts, as in the case of cardiac arrhythmias, additional reconstructions were made at different time points of the R-R interval. At the time of the study, tube current modulation was not used. The estimated radiation dose would be 5-20mSv. Axial data sets are transferred to a remote workstation (Multi-vendor) for post-processing and subsequent evaluation.
CTCA data analysis - Coronary Artery Calcium Score The coronary artery calcium (CACS) score was assessed with the application of dedicated software (Multi-vendor). Coronary artery calcium was identified as a dense area in the coronary artery whose attenuation exceeded the threshold of 130 Hounsfield units (HU). The overall calcium score was calculated according to Agatston score algorithm for each patient.
CTCA data analysis - Coronary Artery Atherosclerotic plaque assessment All CTCA angiograms are evaluated locally by 2 experienced board certified observers. In case of disagreement, a joint reading was performed and a consensus was reached. Coronary arteries were divided into 15-16 segments according to the modified American Heart Association classification and in the case the intermediate branch was present it was added to the classification. All coronary segments were considered in the analysis. First, each segment was classified as assessable or not assessable. All assessable segments were then evaluated for the presence of any atherosclerotic plaque. Axial images and curved multiplanar reconstructions of the segmental vasculature were utilized for the assessment. Coronary plaques were defined as described previously as structures of \>1mm\^2 within and/or adjacent to the coronary artery lumen which are clearly distinguishable from the vessel lumen and surrounding pericardial tissue. Obstructive coronary plaques were defined as plaques resulting in ≥50% luminal narrowing; non obstructive plaques were defined as plaques that resulted in \<50% luminal narrowing. Patients were classified as belonging to one of three groups based on the CTCA findings: 1) patients with normal coronary arteries, 2) patients with non obstructive coronary artery disease, and 3) patients with obstructive coronary artery disease (presence of at least one plaque ≥50%).
Statistical analysis Categorical baseline characteristics, expressed as numbers and percentages, will be compared using the chi-square test. Continuous variables, expressed as mean and standard deviation (SD), will be compared using the 2-tailed t test and analysis of variance if normally distributed or by means of the Kruskal-Wallis method if not normally distributed. A composite end-point of MACE will be used (cardiac death, non-fatal infarction, unstable angina). Cumulative event rates as a function of time were obtained by means of the Kaplan-Meier method. Event curves of MACE will be compared using the log-rank test. Cox regression analysis will be used to identify associations between clinical characteristics and CTCA variables and outcome. Univariate and multivariate analyses will be performed to identify potential predictors. In the multivariate analysis will be included only variables which were significant at univariate analysis. Hazard ratios will be calculated with 95% confidence intervals as an estimate of the risk associated with a particular variable. Statistical analyses will be performed using Excel 2007 software (Microsoft, United States), MedCalc software (version 8.0, United States), STATA software (version 10, United States), SPSS software (version 12.0, United States). p values \<0.05 will be considered statistically significant.
Incremental value of CTCA above CACS will be analyzed. Sub-analysis for the pre-test cardiovascular risk stratification according to the Morise score (low-risk, intermediate risk, high risk) will be performed.
Sample size Based on our experience and data from literature the investigators estimated a sample size of 1000 patients. Considering the retrospective nature of the study, it is possible that at the end the investigators will reach a population \>1000 patients which will anyway let the study continue to the expected 2 years duration.
Primary objectives
* MACE/Major Adverse Cardiovascular Events (i.e. Cardiac Death, Unstable Angina requiring Hospitalization, Acute Myocardial Infarction)
* Prevalence of cardiovascular risk category shifting based on coronary plaque burden
Secondary objectives
* Coronary Revascularizations occurred after CTCA (i.e. PCI/Percutaneous Coronary Revascularization and CABG/Coronary Artery Bypass Graft)
* Prevalence of outliers (i.e. patients lying completely outside the conventional risk stratification; pts with \>3 risk factors and no CAD at CTCA and pts with no risk factors and \>5 coronary segments with CAD)
Institutional Database will be used as data supply. Data will be anonimyzed and pooled (i twill not be possible to detect patients' identity). For this reason the investigators will no task for patients' Informed Consent.
DESIGN The investigators will retrospectively collect data from respective Institutional databases regarding patients who underwent CTCA for suspected CAD in the last 4 years.
General Inclusion criteria Only patients with also Calcium Score
≥64-slice CT technology (or 16-slice CT technology with \>4 year follow-up) Number of patients of at least 100 with complete clinical file and follow-up Minimum follow-up of 12 months Only patients with suspected Coronary Artery Disease
METHODS Study design and patient population This is an observational retrospective study (consecutive patients meeting the inclusion criteria) in patients with suspected coronary artery disease referred to our Institutions for evaluation by Computed Tomography Coronary Angiography (CTCA) starting in January 2003. Participating centers will provide data from 16-slice CTCA (minimum follow-up \>4 years) or superior (i.e. 64-slice CTCA; minimum follow-up 12 months). Each center will have to provide at least 200 patients (with complete file for evaluation).
Patients are usually referred because of symptoms (chest pain, dyspnoea on exertion) and/or abnormal or equivocal stress test and/or high cardiovascular risk profile. Exclusion criteria are renal failure (creatinine clearance \<60ml/min), known previous reaction to iodinated contrast medium and pregnancy, history of Myocardial Infarction, previous revascularization (PCI and/or CABG).
All the patients will be assessed by interview and by data collection from clinical database of the Institution for presence of cardiovascular risk factors and symptoms. The following risk factors will be considered: 1) Hypertension (defined as Arterial Pressure 140/80 mmHg or need for antihypertensive therapy); 2) Hypercholesterolemia (LDL Cholesterol \>130 mg/dl or current treatment with lipid-lowering therapy); 3) Diabetes Mellitus (current need for antidiabetic or insulin therapy); 4) Smoking habit; 5) Obesity (Body Mass Index/BMI\> 30); 6) Family history of cardiac disease. Symptoms will be classified as no symptoms, typical chest pain, atypical chest pain, dyspnoea on exertion. The pre-test cardiovascular risk of the patients will be determined by means of the Morise risk score.
Follow-up Follow-up data of all the patients were obtained by outpatient visit and/or phone contact and/or data collection from clinical database of the Institution. Minimum follow-up will be 6 months. Hospital/patients' records were screened for the occurrence of clinical events to confirm the obtained information. The clinical end-points are: 1) cardiac death, 2) non-fatal acute myocardial infarction, 3) unstable angina requiring hospitalization, 4) percutaneous or surgical revascularization. Cardiac death is defined as death caused by acute myocardial infarction or ventricular arrhythmias. Non-fatal myocardial infarction is defined based on criteria of typical chest pain, elevated cardiac enzyme levels, and typical changes on the electrocardiogram. Revascularization is defined as percutaneous coronary intervention (PCI) with stenting or coronary artery bypass surgery (CABG). The end point was the occurrence of one MACE at follow-up.
Multislice computed tomography data acquisition All examinations were performed with a 16-slice or higher CT system (Multi-vendor). First, a prospectively triggered coronary calcium CT data set was obtained using standardized CT parameters. Thereafter CTCA was performed after the administration of a bolus (60-100ml) non ionic contrast material (Multi-vendor) at flow rate of 4-6ml/s depending on patient status. All injections were performed by power injector via an antecubital vein and were followed by 50 ml of saline bolus chase at the same flow rate. A bolus tracking technique was used to determine the initiation of CT data acquisition. CTCA was performed with the best available parameters, depending on scanner type and generation. The reconstruction slice thickness and increment were 0.5-0.75mm and 0.3-0.5mm respectively. Intra-venous beta-blocker (e.g. atenolol 5-10mg) was administered to all patients with a heart rate \>65 beats/min and without contraindication (known asthma or bronchospasm, systolic blood pressure \<100mmHg). In addition, nitro-glycerine was administered sublingually to all patients, albeit contraindications (known significant aortic stenosis, systolic blood pressure \<100mmHg). Patients with atrial fibrillation or frequent premature beats were included in the study. To obtain optimal image quality, datasets were reconstructed at least at two points of the cardiac cycle using a retrospective ECG gating algorithm (one diastolic cardiac phase usually at -350msec from the R waves and one end-systolic phase at +275msec). In the presence of motion artefacts, as in the case of cardiac arrhythmias, additional reconstructions were made at different time points of the R-R interval. At the time of the study, tube current modulation was not used. The estimated radiation dose would be 5-20mSv. Axial data sets are transferred to a remote workstation (Multi-vendor) for post-processing and subsequent evaluation.
CTCA data analysis - Coronary Artery Calcium Score The coronary artery calcium (CACS) score was assessed with the application of dedicated software (Multi-vendor). Coronary artery calcium was identified as a dense area in the coronary artery whose attenuation exceeded the threshold of 130 Hounsfield units (HU). The overall calcium score was calculated according to Agatston score algorithm for each patient.
CTCA data analysis - Coronary Artery Atherosclerotic plaque assessment All CTCA angiograms are evaluated locally by 2 experienced board certified observers. In case of disagreement, a joint reading was performed and a consensus was reached. Coronary arteries were divided into 15-16 segments according to the modified American Heart Association classification and in the case the intermediate branch was present it was added to the classification. All coronary segments were considered in the analysis. First, each segment was classified as assessable or not assessable. All assessable segments were then evaluated for the presence of any atherosclerotic plaque. Axial images and curved multiplanar reconstructions of the segmental vasculature were utilized for the assessment. Coronary plaques were defined as described previously as structures of \>1mm\^2 within and/or adjacent to the coronary artery lumen which are clearly distinguishable from the vessel lumen and surrounding pericardial tissue. Obstructive coronary plaques were defined as plaques resulting in ≥50% luminal narrowing; non obstructive plaques were defined as plaques that resulted in \<50% luminal narrowing. Patients were classified as belonging to one of three groups based on the CTCA findings: 1) patients with normal coronary arteries, 2) patients with non obstructive coronary artery disease, and 3) patients with obstructive coronary artery disease (presence of at least one plaque ≥50%).
Statistical analysis Categorical baseline characteristics, expressed as numbers and percentages, will be compared using the chi-square test. Continuous variables, expressed as mean and standard deviation (SD), will be compared using the 2-tailed t test and analysis of variance if normally distributed or by means of the Kruskal-Wallis method if not normally distributed. A composite end-point of MACE will be used (cardiac death, non-fatal infarction, unstable angina). Cumulative event rates as a function of time were obtained by means of the Kaplan-Meier method. Event curves of MACE will be compared using the log-rank test. Cox regression analysis will be used to identify associations between clinical characteristics and CTCA variables and outcome. Univariate and multivariate analyses will be performed to identify potential predictors. In the multivariate analysis will be included only variables which were significant at univariate analysis. Hazard ratios will be calculated with 95% confidence intervals as an estimate of the risk associated with a particular variable. Statistical analyses will be performed using Excel 2007 software (Microsoft, United States), MedCalc software (version 8.0, United States), STATA software (version 10, United States), SPSS software (version 12.0, United States). p values \<0.05 will be considered statistically significant.
Incremental value of CTCA above CACS will be analyzed. Sub-analysis for the pre-test cardiovascular risk stratification according to the Morise score (low-risk, intermediate risk, high risk) will be performed.
Sample size Based on our experience and data from literature the investigators estimated a sample size of 1000 patients. Considering the retrospective nature of the study, it is possible that at the end the investigators will reach a population \>1000 patients which will anyway let the study continue to the expected 2 years duration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Coronary Artery Disease
Atherosclerosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Only patients with also Calcium Score
* ≥64-slice CT technology (or 16-slice CT technology with \>4 year follow-up)
* Number of patients of at least 100 with complete clinical file and follow-up
* Minimum follow-up of 12 months
* Only patients with suspected Coronary Artery Disease
* ≥64-slice CT technology (or 16-slice CT technology with \>4 year follow-up)
* Number of patients of at least 100 with complete clinical file and follow-up
* Minimum follow-up of 12 months
* Only patients with suspected Coronary Artery Disease
Exclusion Criteria
* renal failure (creatinine clearance \<60ml/min)
* known previous reaction to iodinated contrast medium and pregnancy
* history of Myocardial Infarction
* previous revascularization (PCI and/or CABG)
* known previous reaction to iodinated contrast medium and pregnancy
* history of Myocardial Infarction
* previous revascularization (PCI and/or CABG)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Società Italiana di Radiologia Medica
OTHER
Sponsor Role
collaborator
Azienda Ospedaliero-Universitaria di Parma
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Filippo Cademartiri
Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Filippo Cademartiri, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Azienda Ospedaliero-Universitaria di Parma, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Policlinico San Donato IRCCS
Milan, MI, Italy
Site Status
RECRUITING
Dibimel, Department of Radiology, University of Palermo
Palermo, PA, Italy
Site Status
RECRUITING
Azienda Ospedaliero-Universitaria di Parma
Parma, PR, Italy
Site Status
RECRUITING
Department of Radiology - Area Vasta 1 - ASUR Marche
Urbino, PU, Italy
Site Status
RECRUITING
Cardiothoracovascular Department cardiovascular radiology Unit, University Hospital Bologna
Bologna, , Italy
Site Status
RECRUITING
AUSL n. 1 Toscana - Ospedale di Carrara
Carrara, , Italy
Site Status
COMPLETED
Azienda Ospedaliera Universitaria San Martino
Genova, , Italy
Site Status
RECRUITING
Sdn Irccs
Naples, , Italy
Site Status
RECRUITING
San Gennaro Hospital
Naples, , Italy
Site Status
RECRUITING
University of Rome "Sapienza", Polo Pontino
Rome, , Italy
Site Status
RECRUITING
Università Sapienza di Roma
Rome, , Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Massimo Midiri, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Maffei E, Seitun S, Martini C, Aldrovandi A, Cervellin G, Tedeschi C, Guaricci A, Messalli G, Catalano O, Cademartiri F. Prognostic value of computed tomography coronary angiography in patients with chest pain of suspected cardiac origin. Radiol Med. 2011 Aug;116(5):690-705. doi: 10.1007/s11547-011-0647-z. Epub 2011 Mar 7. English, Polish.
Reference Type
BACKGROUND
Aldrovandi A, Maffei E, Seitun S, Martini C, Berti E, Grilli R, Messalli G, Weustink AC, Mollet NR, Nieman K, Ardissino D, de Feyter PJ, Krestin GP, Cademartiri F. Major adverse cardiac events and the severity of coronary atherosclerosis assessed by computed tomography coronary angiography in an outpatient population with suspected or known coronary artery disease. J Thorac Imaging. 2012 Jan;27(1):23-8. doi: 10.1097/RTI.0b013e3181f55d0d.
Reference Type
BACKGROUND
Maffei E, Seitun S, Martini C, Aldrovandi A, Arcadi T, Clemente A, Messalli G, Malago R, Weustink A, Mollet N, Nieman K, Ardissino D, de Feyter P, Krestin G, Cademartiri F. Prognostic value of CT coronary angiography: focus on obstructive vs. nonobstructive disease and on the presence of left main disease. Radiol Med. 2011 Feb;116(1):15-31. doi: 10.1007/s11547-010-0592-2. Epub 2010 Oct 6. English, Italian.
Reference Type
BACKGROUND
Aldrovandi A, Maffei E, Palumbo A, Seitun S, Martini C, Brambilla V, Zuccarelli A, Tarantini G, Weustink AC, Mollet NR, Ruffini L, Crisi G, Ardissino D, de Feyter PJ, Krestin GP, Cademartiri F. Prognostic value of computed tomography coronary angiography in patients with suspected coronary artery disease: a 24-month follow-up study. Eur Radiol. 2009 Jul;19(7):1653-60. doi: 10.1007/s00330-009-1344-3. Epub 2009 Feb 18.
Reference Type
BACKGROUND
Van Werkhoven JM, Cademartiri F, Seitun S, Maffei E, Palumbo A, Martini C, Tarantini G, Kroft LJ, de Roos A, Weustink AC, Jukema JW, Ardissino D, Mollet NR, Schuijf JD, Bax JJ. Diabetes: prognostic value of CT coronary angiography--comparison with a nondiabetic population. Radiology. 2010 Jul;256(1):83-92. doi: 10.1148/radiol.1090600.
Reference Type
BACKGROUND
Maffei E, Midiri M, Russo V, Rengo M, Tedeschi C, Spagnolo P, Seitun S, Francone M, Guaricci AI, Carrabba N, Malago R, Cuocolo A, Arcadi T, Catalano OA, Cademartiri F. Rationale, design and methods of CTCA-PRORECAD (Computed Tomography Coronary Angiography Prognostic Registry for Coronary Artery Disease): a multicentre and multivendor registry. Radiol Med. 2013 Jun;118(4):591-607. doi: 10.1007/s11547-012-0912-9. Epub 2013 Jan 28.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://www.sirm.org/
Website of Italian Society of Medical Radiology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SIRM-PRORECAD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III
NCT06793774
RECRUITING
Imaging of Vulnerable Plaques in Coronary Artery Disease by Multidetector Computed Tomography
NCT00482651
COMPLETED
NA
Sequential Coronary CT-angiography and Biomarkers
NCT02394262
UNKNOWN
NA
The Hybrid Combination of CCTA and SPECT and CAG for Evaluation Prognosis of CAD: an Observational Follow-up Study
NCT04554134
COMPLETED
Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease
NCT06843005
RECRUITING
NA
Diagnostic Accuracy of CCTA-derived Versus AngiogRaphy-dErived QuantitativE Flow Ratio (CAREER) Study
NCT04665817
UNKNOWN
Combined Use of Coronary MDCTA, Coronary Doppler Ultrasonography and PET Perfusion in Diagnosing Coronary Artery Disease
NCT00627172
COMPLETED
Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study -
NCT01453712
UNKNOWN
PHASE4
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
NCT03253692
COMPLETED
Implementation of Contemporary Coronary CT Angiography in Clinical Practice
NCT06273033
RECRUITING
Coronary Artery Disease Management Using Multislice Computed Tomography and Magnetic Resonance Imaging
NCT00844220
COMPLETED
NA
Synergy Between morpHOlogical and inflammatoRy Evaluation in Predicting Long-term Coronary Plaque Progression
NCT05436977
COMPLETED
NA
Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging(PARADIGM)
NCT02803411
ACTIVE_NOT_RECRUITING
Biomarkers and Cardiac CT
NCT02381301
RECRUITING
PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
NCT05349084
COMPLETED
NA
68Ga-NODAGA-RGD PET in Patients With an Occluded Coronary Artery
NCT04871217
UNKNOWN
NA
Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care
NCT00783302
COMPLETED
Carotid Plaque Imaging Project (CPIP)
NCT05821894
RECRUITING
Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I
NCT05884008
RECRUITING
Personalization of CM Injection Protocols in Coronary Computed Tomographic Angiography
NCT03292354
COMPLETED
NA
Imaging-based Diagnosis of Diffuse Coronary Artery Disease and Quantification of Cardiac Remodeling in Obesity
NCT03046823
COMPLETED
Comparison of Magnetic Resonance Angiography and Standard Angiography in Diagnosing Atherosclerosis
NCT00001946
COMPLETED
PHASE1
18F Sodium Fluoride PET/CT in Acute Aortic Syndrome
NCT03647566
COMPLETED
Relationship Between Coronary CT Angiography Findings and Prognosis Of Patients Undergoing PCI
NCT07051473
RECRUITING
European Cardio Computer Tomography Registry
NCT01197703
COMPLETED